MedTrace Logo

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

NCT03063892 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-08-07

No results posted yet for this study

Summary

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Conditions

  • Hip Fractures

Interventions

DRUG

Tranexamic Acid (TXA)

Tranexamic acid is an antifibrinolytic used to control bleeding

DRUG

Saline solution

Saline solution is used as the placebo comparator

Sponsors & Collaborators

  • Gregory M Georgiadis MD

    lead OTHER

Principal Investigators

  • Gregory M Georgiadis, MD · ProMedica Toledo Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-30
Primary Completion
2026-07-01
Completion
2026-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03063892 on ClinicalTrials.gov